Download Files:
Products Details
Product Description
– Navafenterol (AZD-8871) is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile[1].
Web ID
– HY-120802
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C38H42N6O6S2
References
– [1]Mònica Aparici, et al. Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist/ β 2-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile. J Pharmacol Exp Ther. 2019 Jul;370(1):127-136.
CAS Number
– 1435519-06-4
Molecular Weight
– 742.91
SMILES
– O=C(C(O)(C1=CC=CS1)C2=CC=CS2)O[C@H]3CC[C@@H](CC3)N(C)CCCN4N=NC5=CC(CNC[C@H](O)C6=CC=C(C7=C6C=CC(N7)=O)O)=CC=C54
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Adrenergic Receptor;mAChR
Isoform
– mAChR3
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
